Roth Capital Predicts Higher Earnings for Journey Medical

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital upped their Q3 2025 earnings per share (EPS) estimates for shares of Journey Medical in a research note issued on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.10 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.16 EPS and FY2029 earnings at $5.83 EPS.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Journey Medical in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $9.67.

Journey Medical Stock Performance

Shares of DERM stock opened at $5.92 on Friday. The stock’s 50-day moving average is $5.05 and its two-hundred day moving average is $5.16. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a 1 year low of $3.20 and a 1 year high of $6.89. The firm has a market cap of $123.67 million, a price-to-earnings ratio of -6.30 and a beta of 0.97.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million.

Institutional Investors Weigh In On Journey Medical

Several institutional investors have recently made changes to their positions in DERM. Cetera Investment Advisers boosted its holdings in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after buying an additional 2,478 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in Journey Medical during the 3rd quarter valued at $66,000. Dimensional Fund Advisors LP purchased a new stake in shares of Journey Medical in the fourth quarter valued at $80,000. Citadel Advisors LLC purchased a new stake in Journey Medical during the 4th quarter worth about $174,000. Finally, Geode Capital Management LLC lifted its holdings in Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after purchasing an additional 12,882 shares in the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Journey Medical

In other Journey Medical news, CEO Claude Maraoui sold 49,271 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the transaction, the chief executive officer now owns 2,003,147 shares in the company, valued at approximately $10,035,766.47. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 105,831 shares of company stock valued at $536,622 in the last ninety days. Insiders own 13.16% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.